Tezspire Shows Success in Eosinophilic Esophagitis Trial

Amgen and AstraZeneca report positive Phase 3 results for their drug in treating the chronic inflammatory condition.

Updated on Oct. 20, 2026 in Asthma

Tezspire Shows Success in Eosinophilic Esophagitis Trial

Live Poll

Is now a good time to pursue newer drug treatments for chronic inflammatory conditions?

Amgen and AstraZeneca presented Phase 3 trial data demonstrating that Tezspire significantly improves outcomes for patients with eosinophilic esophagitis. The drug demonstrated high rates of histologic remission compared to a placebo in the clinical study.

Why it matters

The study suggests that targeting the TSLP protein before inflammation occurs could provide a effective new treatment option for the approximately 470,000 patients in the United States living with this condition.

Patients receiving 420-mg doses of Tezspire achieved a 68.9% histologic remission rate at 24 weeks, compared to 3.5% in the placebo group. Nearly 30% of patients on the higher dose reached total endoscopic remission after one year.

The players

Amgen

Amgen is a global biotechnology company that develops human therapeutics for serious illnesses.

AstraZeneca

AstraZeneca is a multinational pharmaceutical and biotechnology company focused on prescription medicines.

The details

The Crossing trial measured histologic remission by counting peak eosinophils in the esophagus and tracked symptom frequency through the patient-reported Dysphagia Symptom Questionnaire. Patients on the higher 420-mg dose saw a 22-point reduction in dysphagia symptoms, while those in the placebo group saw a 14.7-point reduction.

Late 2021: Tezspire received initial approval for severe asthma.
2022: Dupixent received FDA approval for eosinophilic esophagitis.
October 20, 2026: Amgen and AstraZeneca released the Phase 3 data.
24-week mark: Remission rates were measured in the Crossing trial.
October 2025: Tezspire received approval for chronic rhinosinusitis.

The Big Picture

This clinical advancement follows the precedent set by the 2022 FDA approval of Dupixent for eosinophilic esophagitis. By offering a different molecular target, Tezspire provides an alternative approach to managing this chronic inflammatory disease.

If approved, this treatment could provide a new option for individuals suffering from severe esophageal inflammation that has not responded to other therapies. Patients should consult their doctors about how this drug might eventually fit into their long-term management plans.

The takeaway

Tezspire aims to treat the condition by neutralizing the TSLP protein before inflammation can build up in the esophagus. This represents a significant potential advancement for those currently managing the frequency and severity of dysphagia.